In This Section      
Print This Page

Alan Shuldiner, Ph.D.

Dr. Alan Shuldiner

Dr. Alan Shuldiner is the John L. Whitehurst Professor of Medicine and Associate Dean for Personalized Medicine at the University of Maryland School of Medicine. He directs the UMSOM Program in Personalized and Genomic Medicine, serves as Head of the Division of Endocrinology, Diabetes and Nutrition in the Department of Medicine, and is an Investigator at the Baltimore Veterans Administration Geriatrics Research and Education Clinical Center. He received his BA degree (Chemistry) from Lafayette College and his MD degree from Harvard Medical School. He was a resident in internal medicine at Columbia-Presbyterian Hospital in New York City and a Medical and Senior Staff Fellow in Endocrinology and Metabolism in the Diabetes Branch at the National Institutes of Health. In 1991, he joined the faculty at Johns Hopkins University, Division of Geriatric Medicine and Gerontology as an Assistant Professor, and in 1993 he was promoted to Associate Professor. In 1997 he was recruited to the University of Maryland.

Dr. Shuldiner’s major research interests lie in the genetics of age-related diseases, including of type 2 diabetes, obesity, osteoporosis, and cardiovascular disease - common disorders that contribute significantly to mortality, morbidity, and health care costs in the United States and world-wide. He also works on the pharmaco- and nutri-genomics of these disorders, with a goal of making genomic discoveries that lead to more effective individualized treatment and prevention of these diseases. He is best known for his studies in the Old Order Amish, a homogeneous founder population ideal for genetic studies. He leads a large multidisciplinary research team that uses state-of-the-art molecular genetic statistical and epidemiological methods, including both candidate gene and genome wide approaches. Dr. Shuldiner’s group reported the first null mutation in the APOC3 gene which validates apoCIII as a novel target for the treatment of hypertriglyceridemia. Most recently, through a genome-wide approach, his group identified a common gene variant in CYP2C19 that is associated with poorer response to clopidogrel that many cardiologists now use to individualize anti-platelet therapy. This research is supported by the NIH Pharmacogenomics Research Network and other NIH and foundation grants.

Dr Shuldiner has authored more than 220 original articles in leading journals and 50 reviews and book chapters. He is the recipient of a number of awards, including the prestigious Paul Beeson Physician Faculty Scholar award, the Ellison Medical Foundation Senior Scholar award, and the 2006 University of Maryland Founders Day Researcher of the Year award. Dr. Shuldiner serves on several steering and advisory committees (including NIDDK’s Scientific Council), and study sections related to his expertise in complex disease genetics and translation of genetic discoveries to the clinical setting.